Faes Farma, S.A.

MCE FAE.MC

Faes Farma, S.A. EBITDA for the year ending December 31, 2023: USD 135.69 M

Faes Farma, S.A. EBITDA is USD 135.69 M for the year ending December 31, 2023, a 4.50% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Faes Farma, S.A. EBITDA for the year ending December 31, 2022 was USD 129.84 M, a 2.91% change year over year.
  • Faes Farma, S.A. EBITDA for the year ending December 31, 2021 was USD 126.17 M, a 3.02% change year over year.
  • Faes Farma, S.A. EBITDA for the year ending December 31, 2020 was USD 122.47 M, a 25.13% change year over year.
  • Faes Farma, S.A. EBITDA for the year ending December 31, 2019 was USD 97.88 M, a 18.02% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
MCE: FAE.MC

Faes Farma, S.A.

CEO Mr. Mariano Ucar Angulo
IPO Date Jan. 3, 2000
Location Spain
Headquarters Avenida Autonomía 10
Employees 1,748
Sector Health Care
Industries
Description

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

Similar companies

VIS.MC

Viscofan, S.A.

USD 61.42

0.44%

EBRO.MC

Ebro Foods, S.A.

USD 16.18

0.35%

VID.MC

Vidrala, S.A.

USD 91.52

-0.29%

ALM.MC

Almirall, S.A.

USD 8.60

3.71%

ENC.MC

ENCE Energía y Celulosa, S.A.

USD 3.25

1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email